Abstract
Background
To evaluate uveitis care outcomes in standalone versus a combined ophthalmology-rheumatology clinic.
Methods
Participants were patients aged 18 years and older with a minimum 12-month history of chronic uveitis prior to being referred to the combined uveitis clinic at Kresge Eye Institute and who were treated in the combined clinic for at least 6 months. Best corrected visual acuity (BCVA), objective markers of inflammation, and achieving targeted dose of immunomodulatory therapy (IMT) were compared in the cohort of uveitis patients 6 months prior to and after the initial evaluation in the combined clinic.
Results
Sixty-six percent of study participants were female with a mean age of 51.5 years. BCVA improved from 0.58 logMAR (Snellen: ~20/74) at the initial combined clinic visit to 0.50 logMAR (Snellen: ~20/63) 6 months after the first combined visit (p = 0.0137). The establishment of the combined uveitis clinic led to higher frequency of patients at target dose of IMT: an increase from 49.0% at 6 months prior to the combined visit to 70.1.4% and 79.8% at the initial combined visit and 6 months after the combined visit, respectively.
Conclusion
A combined model of management for chronic uveitis patients wherein rheumatological services are coupled with ophthalmic care leads to improvement in patient clinical outcomes and achieving target therapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Wayne State University School of Medicine, Kresge Eye Institute, Department of Ophthalmology, Detroit, USA (GRID:grid.254444.7) (ISNI:0000 0001 1456 7807)
2 Wayne State University School of Medicine, Department of Rheumatology, Detroit, USA (GRID:grid.254444.7) (ISNI:0000 0001 1456 7807)
3 Henry Ford Hospital, Department of Ophthalmology, Detroit, USA (GRID:grid.413103.4) (ISNI:0000 0001 2160 8953)
4 Wayne State University School of Medicine, Kresge Eye Institute, Department of Ophthalmology, Detroit, USA (GRID:grid.254444.7) (ISNI:0000 0001 1456 7807); Ascension Macomb-Oakland Hospital, Department of Ophthalmology, Warren, USA (GRID:grid.254444.7)